Kyna Conn

Kyna Conn

Auto-generated profile, based on publicly available information

Kyna Conn

Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Clayton, Victoria 3800, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Endocrinology
Verified
Journal Article
Open access
PDF file
SSSheida Shadani
Sheida Shadani
KCKyna Conn
Kyna Conn
ZAZane B Andrews
Zane B Andrews
CFClaire Jennifer Foldi
Claire Jennifer Foldi
The resurgence of interest in psychedelics as treatments for psychiatric disorders necessitates a better understanding of potential sex differences in response to these substances. Sex as a biological variable (SABV) has been historically neglected in medical research, posing limits to our understanding of treatment efficacy. Human studies have provided insights into the efficacy of psychedelics across various diagnoses and aspects of cognition, yet sex-specific effects remain unclear, making it difficult to draw strong conclusions about sex-dependent differences in response to psychedelic treatments. Compounding this further, animal studies used to understand biological mechanisms of psychedelics predominantly use one sex and present mixed neurobiological and behavioral outcomes. Studies that do include both sexes often do not investigate sex differences further, which may hinder the translation of findings to the clinic. In reviewing sex differences in responses to psychedelics, we will highlight the direct interaction between estrogen (the most extensively studied steroid hormone) and the serotonin system (central to the mechanism of action of psychedelics), and the potential that estrogen-serotonin interactions may influence the efficacy of psychedelics in female participants. Estrogen influences serotonin neurotransmission by affecting its synthesis and release, as well as modulating the sensitivity and responsiveness of serotonin receptor subtypes in the brain. This could potentially influence the efficacy of psychedelics in females by modifying their therapeutic efficacy across menstrual cycles and developmental stages. Investigating this interaction in the context of psychedelic research could aid in the advancement of therapeutic outcomes, especially for conditions with sex-specific prevalence.

4 January 2024 in International Journal of Eating Disorders
Verified
Journal Article
Open access
KCK. Conn
K. Conn
KHK. Huang
K. Huang
SGS. Gorrell
S. Gorrell
CFClaire Jennifer Foldi
Claire Jennifer Foldi
Objective: The development of novel treatments for anorexia nervosa (AN) requires a detailed understanding of the biological underpinnings of specific, commonly occurring symptoms, including compulsive exercise. There is considerable bio‐behavioral overlap between AN and obsessive‐compulsive disorder (OCD), therefore it is plausible that similar mechanisms underlie compulsive behavior in both populations. While the association between these conditions is widely acknowledged, defining the shared mechanisms for compulsive behavior in AN and OCD requires a novel approach.Methods: We present an argument that a better understanding of the neurobiological mechanisms that underpin compulsive exercise in AN can be achieved in two critical ways. First, by applying a framework of the neuronal control of OCD to exercise behavior in AN, and second, by taking better advantage of the activity‐based anorexia (ABA) rodent model to directly test this framework in the context of feeding pathology.Results: A cross‐disciplinary approach that spans preclinical, neuroimaging, and clinical research as well as compulsive neurocircuitry and behavior can advance our understanding of when, why, and how compulsive exercise develops in the context of AN and provide targets for novel treatment strategies.Discussion: In this article, we (i) link the expression of compulsive behavior in AN and OCD via a transition between goal‐directed and habitual behavior, (ii) present disrupted cortico‐striatal circuitry as a key substrate for the development of compulsive behavior in both conditions, and (iii) highlight the utility of the ABA rodent model to better understand the mechanisms of compulsive behavior relevant to AN.Public Significance: Individuals with AN who exercise compulsively are at risk of worse health outcomes and have poorer responses to standard treatments. However, when, why, and how compulsive exercise develops in AN remains inadequately understood. Identifying whether the neural circuitry underlying compulsive behavior in OCD also controls hyperactivity in the activity‐based anorexia model will aid in the development of novel eating disorder treatment strategies for this high‐risk population.

30 June 2023 in eLife
Verified
Journal Article
Open access
KHKaixin Huang
Kaixin Huang
LMLaura K Milton
Laura K Milton
HDHarry Dempsey
Harry Dempsey
SPStephen J Power
Stephen J Power
KCKyna-Anne Conn
Kyna-Anne Conn
CFClaire Jennifer Foldi
Claire Jennifer Foldi
Anorexia nervosa has among the highest mortality rates of any psychiatric disorder and is characterized by cognitive inflexibility that persists after weight recovery and contributes to the chronic nature of the condition. What remains unknown is whether cognitive inflexibility predisposes individuals to anorexia nervosa, a question that is difficult to address in human studies. Our previous work using the most well-established animal model of anorexia nervosa, known as activity-based anorexia (ABA) identified a neurobiological link between cognitive inflexibility and susceptibility to pathological weight loss in female rats. However, testing flexible learning prior to exposure to ABA in the same animals has been thus far impossible due to the length of training required and the necessity of daily handling, which can itself influence the development of ABA. Here, we describe experiments that validate and optimize the first fully-automated and experimenter-free touchscreen cognitive testing system for rats and use this novel system to examine the reciprocal links between reversal learning (an assay of cognitive flexibility) and weight loss in the ABA model. First, we show substantially reduced testing time and increased throughput compared to conventional touchscreen testing methods because animals engage in test sessions at their own direction and can complete multiple sessions per day without experimenter involvement. We also show that, contrary to expectations, cognitive inflexibility measured by this reversal learning task does not predispose rats to pathological weight loss in ABA. Instead, rats that were predisposed to weight loss in ABA were more quickly able to learn this reversal task prior to ABA exposure. Intriguingly, we show reciprocal links between ABA exposure and cognitive flexibility, with ABA-exposed (but weight-recovered) rats performing much worse than ABA naïve rats on the reversal learning task, an impairment that did not occur to the same extent in rats exposed to food restriction conditions alone. On the other hand, animals that had been trained on reversal learning were better able to resist weight loss upon subsequent exposure to the ABA model. We also uncovered some stable behavioral differences between ABA susceptible versus resistant rats during touchscreen test sessions using machine learning tools that highlight possible predictors of anorectic phenotypes. These findings shed new light on the relationship between cognitive inflexibility and pathological weight loss and provide targets for future studies using the ABA model to investigate potential novel pharmacotherapies for anorexia nervosa.

13 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KCKyna Conn
Kyna Conn
LMLaura K Milton
Laura K Milton
KHKaixin Huang
Kaixin Huang
HMHermany Munguba
Hermany Munguba
JRJanika Ruuska
Janika Ruuska
CFClaire Jennifer Foldi
Claire Jennifer Foldi
Psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials for the treatment of anorexia nervosa (AN), a condition that is characterised by persistent cognitive inflexibility. Considering that enhanced cognitive flexibility after psilocybin treatment is reported to occur in individuals with depression, it is plausible that psilocybin could improve symptoms of AN by breaking down cognitive inflexibility. A mechanistic understanding of the actions of psilocybin is required to tailor the clinical application of psilocybin to individuals most likely to respond with positive outcomes. This can only be achieved using incisive neurobiological approaches in animal models. Here, we use the activity-based anorexia (ABA) rat model and comprehensively assess aspects of reinforcement learning to show that psilocybin (post-acutely) improves body weight maintenance in female rats and facilitates cognitive flexibility, specifically via improved adaptation to the initial reversal of reward contingencies. Further, we reveal the involvement of signalling through the serotonin (5-HT) 1A and 5-HT2A receptor subtypes in specific aspects of learning, demonstrating that 5-HT1A antagonism negates the cognitive enhancing effects of psilocybin. Moreover, we show that psilocybin elicits a transient increase and decrease in cortical transcription of these receptors ( Htr2a and Htr1a , respectively), and a further reduction in the abundance of Htr2a transcripts in rats exposed to the ABA model. Together, these findings support the hypothesis that psilocybin could ameliorate cognitive inflexibility in the context of AN and highlight a need to better understand the therapeutic mechanisms independent of 5-HT2A receptor binding.

20 April 2023 in Neuropharmacology
Verified
Journal Article
Closed access
KCKyna-Anne Conn
Kyna-Anne Conn
SZSimin Zou
Simin Zou
JDJoyosmita Das
Joyosmita Das
SASuzy Alexander
Suzy Alexander
TBThomas H.J. Burne
Thomas H.J. Burne
JKJames P. Kesby
James P. Kesby

18 June 2025 in Neuropharmacology
Verified
Journal Article
Open access
KCKyna-Anne Conn
Kyna-Anne Conn
JDJoyosmita Das
Joyosmita Das
SASuzy Alexander
Suzy Alexander
TBThomas Hj. Burne
Thomas Hj. Burne
JKJames P. Kesby
James P. Kesby
People with schizophrenia often show impairments in cognitive flexibility, which is a key aspect of executive function, and this contributes to poor functional outcomes. Neuroimaging studies in schizophrenia have implicated dysfunction within the dorsomedial striatum (DMS), which is a subcortical brain region integral to reversal learning, i.e., a form of cognitive flexibility involving adapting behaviour in response to changing reward contingencies. Given its integral role in these processes, understanding the biological and cognitive consequences related to DMS dysfunction may inform therapeutic strategies to mitigate cognitive inflexibility. This study employed a serial reversal learning paradigm to examine decision-making under probabilistic uncertainty and investigated the effects of DREAADs-based chemogenetic inhibition of the DMS on performance and the subsequent activity of corticostriatal circuitry in male C57BL/6J mice. Inhibition of DMS activity impaired reversal learning under probabilistic uncertainty, specifically disrupting reward-based decision-making strategies such as by reducing win-stay behaviour. Furthermore, DMS inactivation led to diminished corticostriatal network co-activation during reversal learning, with pronounced reductions in the efficiency of anterior cingulate, orbitofrontal, and insular cortices-cortical regions crucial for flexible learning. These results suggest that inhibiting DMS function disrupts behavioural adaptation as well as corticostriatal co-activation, a mechanism that potentially contributes to the cognitive inflexibility observed in schizophrenia. By elucidating the neural substrates of reversal learning deficits, this study provides insights into the mechanisms by which DMS inhibition affects cognitive flexibility and highlights potential targets for therapeutic intervention in schizophrenia-relevant cognitive impairments.